On May 16, 2018 Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Shorts Rose By 2.99%

May 16, 2018 - By Mark Mitchell

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Corporate Logo

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) reported an increase of 2.99% in short interest. It was issued in May by FINRA the 6.79 million short interest on ARWR. The up change of 2.99% from 6.60 million shares was reported. 9 days will cost ARWR with 736,000 average volume to restore its previous position. Arrowhead Pharmaceuticals Inc float short is 9.95%.

The stock decreased 0.94% or $0.09 during the last trading session, touching $9.51.Arrowhead Pharmaceuticals, Inc. has volume of 1.16 million shares. Since May 16, 2017 ARWR has risen 265.61% and is uptrending. ARWR outperformed the S&P500 by 254.06%.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States.The company has $832.86 million market cap. The Company’s pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders.Last it reported negative earnings. The firm also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Coverage

In total 7 analysts cover Arrowhead Research (NASDAQ:ARWR). “Buy” rating has 5, “Sell” are 0, while 2 are “Hold”. (NASDAQ:ARWR) has 71% bullish analysts. 12 are the (NASDAQ:ARWR)’s ratings reports on May 16, 2018 according to StockzIntelligence Inc. The stock rating was maintained by FBR Capital with “Hold” on Tuesday, March 27. On Monday, February 12 the company was maintained by FBR Capital. On Monday, November 27 Piper Jaffray upgraded Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) rating. Piper Jaffray has “Buy” rating and $5.5 target. On Monday, March 12 the rating was maintained by FBR Capital with “Hold”. The stock rating was maintained by B. Riley & Co with “Neutral” on Monday, February 12. On Monday, November 27 the rating was upgraded by PiperJaffray to “Overweight”. On Wednesday, May 9 the stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has “Overweight” rating given by Cantor Fitzgerald. On Monday, February 12 the stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) earned “Neutral” rating by Cantor Fitzgerald.

There’s a substantial Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news posted by Schaeffersresearch.com. It’s a report titled: “2 Upgraded Drug Stocks Squeezing Shorts” on May 09, 2018.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: